Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2021-04-30 Regulatory Filings
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed correspondence letter addressed to the U.S. Securities and Exchange Commission regarding a Registration Statement on Form S-1 filed by TScan Therapeutics, Inc. It discusses confidential treatment requests, valuation methodologies for common stock, and details related to the company's IPO pricing and equity awards. The presence of Form S-1 and the focus on IPO registration and valuation indicate this is related to a capital raising event. The document is not a full financial report, earnings release, or management discussion, but rather a regulatory filing responding to SEC comments on the registration statement. It is not a report publication announcement or certification letter but a substantive regulatory correspondence. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-04-30 English
Regulatory Filings 2021
Regulatory Filings
2021-04-30 English
Regulatory Filings 2021
Regulatory Filings
2021-04-29 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from TScan Therapeutics, Inc. to the U.S. Securities and Exchange Commission (SEC) staff regarding comments on a Draft Registration Statement on Form S-1. The letter addresses specific SEC comments on various sections of the Registration Statement, including the Overview, Pipeline, Business, MD&A, and License Agreements. The document is not the Registration Statement itself but a correspondence responding to SEC review comments on the draft filing. It contains no financial statements or substantive financial data but rather explanations and revisions to the draft S-1 filing. Therefore, this document is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory correspondence and filings that do not fit other categories.
2021-04-23 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) for TScan Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes detailed information about the company, the offering, risk factors, management, financials, and other disclosures typical of an S-1 filing. This type of document is a capital markets filing related to fundraising and securities registration, not an annual report, earnings release, or other report types. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement or notice, so it is not RPA or RNS. Confidence is high due to the clear identification of the form and content.
2021-04-23 English
Regulatory Filings 2021
Regulatory Filings
2021-04-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.